HER2 Support Group Forums
>
her2group
Dr. Slamon describes results of genomic seqncng to determine who benefits from adding
User Name
Remember Me?
Password
Register
Gallery
FAQ
Members List
Calendar
Today's Posts
Search
Search Forums
Show Threads
Show Posts
Advanced Search
Search Gallery
Advanced Search
Go to Page...
Thread Tools
Display Modes
06-06-2015, 09:01 PM
#
1
Lani
Senior Member
Join Date: Mar 2006
Posts: 4,778
Dr. Slamon describes results of genomic seqncng to determine who benefits from adding
everolimus (an mTor inhibitor which ffeecets the PI3k pathway) to herceptin in Stage IV patients
http://meetinglibrary.asco.org/content/112020?media=vm
Lani
View Public Profile
Send a private message to Lani
Find More Posts by Lani
06-07-2015, 03:44 AM
#
2
sarah
Senior Member
Join Date: Sep 2005
Location: france
Posts: 1,648
Re: Dr. Slamon describes results of genomic seqncng to determine who benefits from ad
yes interesting and here's more on the subject:
http://www.ascopost.com/ViewNews.aspx?nid=20674
sarah
__________________
sarah
View Public Profile
Send a private message to sarah
Find More Posts by sarah
«
Previous Thread
|
Next Thread
»
Thread Tools
Show Printable Version
Email this Page
Display Modes
Linear Mode
Switch to Hybrid Mode
Switch to Threaded Mode
Posting Rules
You
may not
post new threads
You
may not
post replies
You
may not
post attachments
You
may not
edit your posts
BB code
is
On
Smilies
are
On
[IMG]
code is
On
HTML code is
Off
Forum Rules
Forum Jump
User Control Panel
Private Messages
Subscriptions
Who's Online
Search Forums
Forums Home
her2group
Herceptin / Tykerb
Caregivers Corner
Diet and Nutrition
Inflammatory Breast Cancer
Keeping Your Mind Off of BC
Profiles In Courage
My Healthcare Team
Clinical Trials
Articles of Interest
Events and Social Calendar
Breast Cancer Meeting Highlights
General Cancer News
Breast Cancer News
Breast Cancer Newsfeed
All times are GMT -7. The time now is
12:40 PM
.